Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2008-03-13

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm701212mPMID 18335975PMCID PMC3901315
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.

  2007cited by this paper
• Thiazolidinediones Modulate the Expression of β-Catenin and Other Cell-Cycle Regulatory Proteins by Targeting the F-Box Proteins of Skp1-Cul1-F-box Protein E3 Ubiquitin Ligase Independently of Peroxisome Proliferator-Activated Receptor γ

  2007cited by this paper
• Peroxisome Proliferator-Activated Receptor γ-Independent Repression of Prostate-Specific Antigen Expression by Thiazolidinediones in Prostate Cancer Cells

  2006cited by this paper
• Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.

  2006cited by this paper
• Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells.

  2006cited by this paper
• Peroxisome Proliferator-Activated Receptor γ-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells

  2005cited by this paper
• Small-interfering RNA–induced androgen receptor silencing leads to apoptotic cell death in prostate cancer

  2005cited by this paper
• Androgens and prostate cancer: are the descriptors valid?

  2005cited by this paper
• Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.

  2005cited by this paper
• Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.

  2005cited by this paper
• Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence

  2004cited by this paper
• Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta.

  2004cited by this paper
• The androgen receptor: a potential target for therapy of prostate cancer.

  2004cited by this paper
• Chemoprevention of Prostate Cancer: Current Status and Future Directions

  2004cited by this paper
• Mechanisms of androgen-refractory prostate cancer.

  2004cited by this paper
• Approaches to understanding the importance and clinical implications of peroxisome proliferator‐activated receptor gamma (PPARγ) signaling in prostate cancer

  2004cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• Androgen receptor outwits prostate cancer drugs

  2004cited by this paper
• Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity.

  2003cited by this paper
• Peroxisome proliferator-activated receptor γ and cancers

  2003cited by this paper
• Peroxisome proliferator-activated receptor gamma and cancers.

  2003cited by this paper
• Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells.

  2003cited by this paper
• Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication.

  2003cited by this paper
• Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication

  2003cited by this paper
• The role of the androgen receptor in prostate cancer.

  2002cited by this paper
• Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells

  2002cited by this paper
• 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells.

  2001cited by this paper
• Androgen receptor signaling in androgen-refractory prostate cancer.

  2001cited by this paper
• Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.

  2001cited by this paper
• Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway

  2001cited by this paper
• 15-Deoxy-Δ12,14-prostaglandin J2 and Thiazolidinediones Activate the MEK/ERK Pathway through Phosphatidylinositol 3-Kinase in Vascular Smooth Muscle Cells*

  2001cited by this paper
• Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells.

  2000cited by this paper
• Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.

  2000cited by this paper
• Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells.

  1999cited by this paper
• Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor.

  1999cited by this paper
• Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer.

  1996cited by this paper
• On the Reactivity of the Exocyclic Double Bond in 5-Arylidene-3-aryl-2,4-thiazolidinediones; Their Reaction with Diazoalkanes, p-Thiocresol and Piperidine

  1960cited by this paper

• Thiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes.

  2023cites this paper
• An Efficient One Pot Multicomponent Synthesis of Coumarino Pyrazolyl Thiazolidinones

  2020cites this paper
• The progress and development of GLUT1 inhibitors targeting cancer energy metabolism.

  2019cites this paper
• Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.

  2016cites this paper
• Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?

  2016cites this paper
• Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones.

  2014cites this paper
• Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.

  2014cites this paper
• Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.

  2013cites this paper
• PPARγ-independent activity of thiazolidinediones: a promising mechanism of action for new anticancer drugs?

  2012cites this paper
• Targeting the Oncogenic E3 Ligase Skp2 in Prostate and Breast Cancer Cells with a Novel Energy Restriction-Mimetic Agent

  2012cites this paper
• Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction‐mimetic agent

  2012cites this paper
• Effect of structural modifications on 3‐(3,5‐dichlorophenyl)‐2,4‐thiazolidinedione‐induced hepatotoxicity in Fischer 344 rats

  2012cites this paper
• Development of a novel class of glucose transporter inhibitors.

  2012cites this paper
• Energy Restriction-mimetic Agents Induce Apoptosis in Prostate Cancer Cells in Part through Epigenetic Activation of KLF6 Tumor Suppressor Gene Expression*

  2011cites this paper
• Pleiotropic Effects of Glitazones: A Double Edge Sword?

  2011cites this paper
• The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.

  2010cites this paper
• Development of novel adenosine monophosphate-activated protein kinase activators.

  2010cites this paper
• New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines

  2010cites this paper
• Energy Restriction as an Antitumor Target of Thiazolidinediones*

  2010cites this paper
• Natural product-inspired synthesis of thiazolidine and thiazolidinone compounds and their anticancer activities.

  2010cites this paper
• New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

  2010cites this paper
• Thiazolidinediones Mimic Glucose Starvation in Facilitating Sp1 Degradation through the Up-Regulation of β-Transducin Repeat-Containing Protein

  2009influential citation
• Rhodanine as a privileged scaffold in drug discovery.

  2009cites this paper
• PPARgamma-independent antitumor effects of thiazolidinediones.

  2009cites this paper
• PPAR γ-Independent Antitumor Effects of Thiazolidinediones

  2009cites this paper
• Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.

  2009cites this paper